The UK’s cell and gene therapy sector is on the threshold of becoming a global leader in the field. While present challenges include the supply of equipment and skills gaps, Innovation Hubs aim to bridge these through collaboration.

Discover the key strategies and financial nuances of gene therapy like outcome-driven contracts, payment plans, and shared financial agreements

Improving process efficiency is a key approach to factor in when looking at how cell therapy manufacture can be made more sustainable.

Given the widespread incidence of cancers and cardiovascular diseases, having sufficient means to model their behaviour is vital to the development of new treatments. Maintaining tissue contexts in disease modelling is crucial for developing a comprehensive understanding of how different diseases behave.

3D cell modelling can help develop understandings of disease pathologies, facilitating the investigation of how tissues react to certain treatments without causing undue harm or risk to the patients who need them.

Developers looking to integrate digitalisation approaches into their pipeline should ensure that they choose a sensible architecture, rather than simply automating for the sake of it.

With a host of factors to consider in cell and gene manufacture, upscaling is still no small task. However, as industry experience accumulates and new technologies arrive on the market, there are an increasing number of options for developers looking to get their therapeutic on the road to the clinic.

Regulatory approval is, as ever, a crucial factor to bear in mind during the later phases of clinical trials. Regardless of the cell line approach chosen, keeping a consistent process and product output is key for establishing a successful project without it being hamstrung at the final hurdle.

Securing regulatory approval is often the end goal in the development of a new therapeutic product. But what steps can be taken to avoid some of the common curveballs encountered in the industry?

Genentech are developing several complex gastrointestinal in vitro models, including the innovative apical-out organoids.

Exploring academic perspectives on 3D bioprinting techniques for cancer and disease indication models.

Elodie Vandenhaute, Project Director at HCS Pharma, leads a discussion group on utilising multi-cell type models to understand diseases, cells, and therapeutic mechanisms.

The lack of predictive models is a highly limiting factor in the efficacy of projects designed to find new therapeutic targets. Cutting-edge organoid models may be the key to overcoming these challenges and could improve the prediction candidate drug molecules' clinical success.

Udayanath Aich, Director at Bristol Myers Squibb, leads a Discussion Group on leveraging advanced technologies and biologics to mitigate challenges.

What will the future hold for autologous cell and gene therapy manufacturing? Tigen Pharma SA, share their predictions on the prospect of disruptive innovation for the industry.

New Data from the Cell and Gene Therapy Catapult shows improved yield, quality, and process efficiency for AAV manufacturing using osmolality.

Hemant Dhamne, Head of Process Development of Gene Therapy at King's College London, discusses the process of viral vector production, the current and future manufacturing technologies, and challenges in the field.

Can advanced analytical processing and real-time data monitoring conquer the complexity of Bio-pharmaceutical manufacturing? We ask Udayanath Aich, Director at Bristol Myers Squibb.

Tuhina Bhattacharya, Associate Director of CMC Biologics at Corbus Pharmaceuticals, leads a Discussion Group on the future of downstream bioprocessing technologies.

How can combinatorial screening of diverse variables in process development optimise cell and gene therapies? Marina Tarunina, Research Director at Plasticell, investigates.